Anti-cd137 constructs, multispecific antibody and uses thereof
AssigneeShanghai Henlius Biotech, Inc.
InventorsJie XUE, Wei-Dong JIANG, Wenfeng XU, Weijun FENG
Life of this patent
Estimating the term…
Abstract
The present invention provides anti-CD137 constructs that bind to CD137, including multispecific anti-CD137 antibodies with binding specificity for CD137 and one or more additional antigen, and methods of using the same. In certain embodiments, the one or more additional antigen comprises epidermal growth factor receptor (EGFR).
Claims42
A multispecific antibody that binds to CD137 and EGFR, comprising a first antibody moiety that binds to CD137 and a second antibody moiety that binds to EGFR;
- wherein the first antibody moiety comprises a heavy chain variable region (VH) comprising HC-CDR1, HC-CDR2 and HC-CDR3 domains and a light chain variable region (VL) comprising LC-CDR1, LC-CDR2 and LC-CDR3 domains that are selected from the group consisting of:
- a) the VH comprises the HC-CDR1 comprising the amino acid sequence of SEQ ID NO:
- 1, the HC-CDR2 comprising the amino acid sequence of SEQ ID NO:
- 2, and the HC-CDR3 comprising the amino acid sequence of SEQ ID NO:
- 3, and the VL comprises the LC-CDR1 comprising the amino acid sequence of SEQ ID NO:
- 4, the LC-CDR2 comprising the amino acid sequence of SEQ ID NO:
- 5, and the LC-CDR3 comprising the amino acid sequence of SEQ ID NO:
- 6;
- b) the VH comprises the HC-CDR1 comprising the amino acid sequence of SEQ ID NO:
- 11, the HC-CDR2 comprising the amino acid sequence of SEQ ID NO:
- 12, and the HC-CDR3 comprising the amino acid sequence of SEQ ID NO:
- 13, and the VL comprises the LC-CDR1 comprising the amino acid sequence of SEQ ID NO:
- 14, the LC-CDR2 comprising the amino acid sequence of SEQ ID NO:
- 15, and the LC-CDR3 comprising the amino acid sequence of SEQ ID NO:
- 16;
- c) the VH comprises the HC-CDR1 comprising the amino acid sequence of SEQ ID NO:
- 21, the HC-CDR2 comprising the amino acid sequence of SEQ ID NO:
- 22, and the HC-CDR3 comprising the amino acid sequence of SEQ ID NO:
- 23, and the VL comprises the LC-CDR1 comprising the amino acid sequence of SEQ ID NO:
- 24, the LC-CDR2 comprising the amino acid sequence of SEQ ID NO:
- 25, and the LC-CDR3 comprising the amino acid sequence of SEQ ID NO:
- 26;
- d) the VH comprises the HC-CDR1 comprising the amino acid sequence of SEQ ID NO:
- 31, the HC-CDR2 comprising the amino acid sequence of SEQ ID NO:
- 32, and the HC-CDR3 comprising the amino acid sequence of SEQ ID NO:
- 33, and the VL comprises the LC-CDR1 comprising the amino acid sequence of SEQ ID NO:
- 34, the LC-CDR2 comprising the amino acid sequence of SEQ ID NO:
- 35, and the LC-CDR3 comprising the amino acid sequence of SEQ ID NO:
- 36;
- e) the VH comprises the HC-CDR1 comprising the amino acid sequence of SEQ ID NO:
- 41, the HC-CDR2 comprising the amino acid sequence of SEQ ID NO:
- 42, and the HC-CDR3 comprising the amino acid sequence of SEQ ID NO:
- 43, and the VL comprises the LC-CDR1 comprising the amino acid sequence of SEQ ID NO:
- 44, the LC-CDR2 comprising the amino acid sequence of SEQ ID NO:
- 45, and the LC-CDR3 comprising the amino acid sequence of SEQ ID NO:
- 46;
- f) the VH comprises the HC-CDR1 comprising the amino acid sequence of SEQ ID NO:
- 51, the HC-CDR2 comprising the amino acid sequence of SEQ ID NO:
- 52, and the HC-CDR3 comprising the amino acid sequence of SEQ ID NO:
- 53, and the VL comprises the LC-CDR1 comprising the amino acid sequence of SEQ ID NO:
- 54, the LC-CDR2 comprising the amino acid sequence of SEQ ID NO:
- 55, and the LC-CDR3 comprising the amino acid sequence of SEQ ID NO:
- 56;
- g) the VH comprises the HC-CDR1 comprising the amino acid sequence of SEQ ID NO:
- 61, the HC-CDR2 comprising the amino acid sequence of SEQ ID NO:
- 62, and the HC-CDR3 comprising the amino acid sequence of SEQ ID NO:
- 63, and the VL comprises the LC-CDR1 comprising the amino acid sequence of SEQ ID NO:
- 64, the LC-CDR2 comprising the amino acid sequence of SEQ ID NO:
- 65, and the LC-CDR3 comprising the amino acid sequence of SEQ ID NO:
- 66;
- h) the VH comprises the HC-CDR1 comprising the amino acid sequence of SEQ ID NO:
- 71, the HC-CDR2 comprising the amino acid sequence of SEQ ID NO:
- 72, and the HC-CDR3 comprising the amino acid sequence of SEQ ID NO:
- 73, and the VL comprises the LC-CDR1 comprising the amino acid sequence of SEQ ID NO:
- 74, the LC-CDR2 comprising the amino acid sequence of SEQ ID NO:
- 75, and the LC-CDR3 comprising the amino acid sequence of SEQ ID NO:
- 76;
- i) the VH comprises the HC-CDR1 comprising the amino acid sequence of SEQ ID NO:
- 81, the HC-CDR2 comprising the amino acid sequence of SEQ ID NO:
- 82, and the HC-CDR3 comprising the amino acid sequence of SEQ ID NO:
- 83, and the VL comprises the LC-CDR1 comprising the amino acid sequence of SEQ ID NO:
- 84, the LC-CDR2 comprising the amino acid sequence of SEQ ID NO:
- 85, and the LC-CDR3 comprising the amino acid sequence of SEQ ID NO:
- 86;
- i) the VH comprises the HC-CDR1 comprising the amino acid sequence of SEQ ID NO:
- 91, the HC-CDR2 comprising the amino acid sequence of SEQ ID NO:
- 92, and the HC-CDR3 comprising the amino acid sequence of SEQ ID NO:
- 93, and the VL comprises the LC-CDR1 comprising the amino acid sequence of SEQ ID NO:
- 94, the LC-CDR2 comprising the amino acid sequence of SEQ ID NO:
- 95, and the LC-CDR3 comprising the amino acid sequence of SEQ ID NO:
- 96;
- k) the VH comprises the HC-CDR1 comprising the amino acid sequence of SEQ ID NO:
- 101, the HC-CDR2 comprising the amino acid sequence of SEQ ID NO:
- 102, and the HC-CDR3 comprising the amino acid sequence of SEQ ID NO:
- 103, and the VL comprises the LC-CDR1 comprising the amino acid sequence of SEQ ID NO:
- 104, the LC-CDR2 comprising the amino acid sequence of SEQ ID NO:
- 105, and the LC-CDR3 comprising the amino acid sequence of SEQ ID NO:
- 106;
- l) the VH comprises the HC-CDR1 comprising the amino acid sequence of SEQ ID NO:
- 111, the HC-CDR2 comprising the amino acid sequence of SEQ ID NO:
- 112, and the HC-CDR3 comprising the amino acid sequence of SEQ ID NO:
- 113, and the VL comprises the LC-CDR1 comprising the amino acid sequence of SEQ ID NO:
- 114, the LC-CDR2 comprising the amino acid sequence of SEQ ID NO:
- 115, and the LC-CDR3 comprising the amino acid sequence of SEQ ID NO:
- 116;
- m) the VH comprises the HC-CDR1 comprising the amino acid sequence of SEQ ID NO:
- 121, the HC-CDR2 comprising the amino acid sequence of SEQ ID NO:
- 122, and the HC-CDR3 comprising the amino acid sequence of SEQ ID NO:
- 123, and the VL comprises the LC-CDR1 comprising the amino acid sequence of SEQ ID NO:
- 124, the LC-CDR2 comprising the amino acid sequence of SEQ ID NO:
- 125, and the LC-CDR3 comprising the amino acid sequence of SEQ ID NO:
- 126;
- n) the VH comprises the HC-CDR1 comprising the amino acid sequence of SEQ ID NO:
- 131, the HC-CDR2 comprising the amino acid sequence of SEQ ID NO:
- 132, and the HC-CDR3 comprising the amino acid sequence of SEQ ID NO:
- 133, and the VL comprises the LC-CDR1 comprising the amino acid sequence of SEQ ID NO:
- 134, the LC-CDR2 comprising the amino acid sequence of SEQ ID NO:
- 135, and the LC-CDR3 comprising the amino acid sequence of SEQ ID NO:
- 136;
- o) the VH comprises the HC-CDR1 comprising the amino acid sequence of SEQ ID NO:
- 261, the HC-CDR2 comprising the amino acid sequence of SEQ ID NO:
- 262, and the HC-CDR3 comprising the amino acid sequence of SEQ ID NO:
- 263, and the VL comprises the LC-CDR1 comprising the amino acid sequence of SEQ ID NO:
- 264, the LC-CDR2 comprising the amino acid sequence of SEQ ID NO:
- 265, and the LC-CDR3 comprising the amino acid sequence of SEQ ID NO:
- 266;
- and
- p) the VH comprises the HC-CDR1 comprising the amino acid sequence of SEQ ID NO:
- 271, the HC-CDR2 comprising the amino acid sequence of SEQ ID NO:
- 272, and the HC-CDR3 comprising the amino acid sequence of SEQ ID NO:
- 273, and the VL comprises the LC-CDR1 comprising the amino acid sequence of SEQ ID NO:
- 274, the LC-CDR2 comprising the amino acid sequence of SEQ ID NO:
- 275, and the LC-CDR3 comprising the amino acid sequence of SEQ ID NO:
- 276.
2-17. (canceled)
19-20. (canceled)
22-23. (canceled)
25-26. (canceled)
28-29. (canceled)
31-46. (canceled)
48-49. (canceled)
55-56. (canceled)
58-59. (canceled)
61-63. (canceled)
(canceled)
70-83. (canceled)
(canceled)
92-101. (canceled)
(canceled)
Dependencies are inferred from the claim text.